The medical technology industry in Australia is crucial for the economy, but there is a need to address challenges in attracting talent and promoting innovation in order to support its growth and potential, according to an extensive report on medical technology in Australia.
In June 2023 the Medical Technology Association of Australia (MTAA) launched The Value of MedTech Report – a major study quantifying the difference the MedTech industry makes to the lives of Australian patients, the healthcare system and the Australian economy.
The report was prepared using analysis by the Nous Group for the Medical Technology Association of Australia with support from MTPConnect and Pathology Technology Australia.
As part of MTAA’s annual MedTech on the Hill initiative, the report was formally launched in June 2023 by the Minister for Health and Aged Care, the Hon. Mark Butler MP, in Parliament House during an event attended by Ministers, Members of Parliament, Senators, and key health sector stakeholders.
The Report brings to light the significant value and contribution of MedTech in Australia, particularly to Australia’s healthcare system, industry development, employment and the wider economy.
Australian Health Journal spoke with MTAA CEO, Ian Burgess and MTAA Policy Manager, Pravin Siriwardena about the report and its key findings.
About MTAA
The Medical Technology Association of Australia (MTAA) is the national association representing companies in the medical technology industry. MTAA aims to ensure the benefits of modern, innovative and reliable medical technology are delivered effectively to provide better health outcomes to the Australian community.
MTAA represents manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and management of disease and disability. The range of medical technology is diverse with products ranging from familiar items such as syringes and wound dressings, through to high-technology implanted devices such as pacemakers, defibrillators, hip and other orthopaedic implants. Products also include hospital and diagnostic imaging equipment such as ultrasounds and magnetic resonance imaging machines.
You Might also like
-
Michelle Fenwick – Northern Health
The outskirts of Melbourne is experiencing significant population growth over the next 10 years and Northern Health has taken preemptive steps to ensure the supply of new talented healthcare staff as well as develop the culture of the workplace.
Michelle Fenwick, the Executive Director of Northern Health spoke with our reporter Anne Dao on the challenges of this urban growth over the past 3 years. By 2031 the region is expected to increase in population by 63%. Added to this is hiring and training the right workforce to align with the clinical care needs of people coming into the healthcare centres.
Culture is forming in a growing organisation with approximately 70% of staff having been at Northern Health less than 4 years. However there is opportunity for clinical staff to accelerate their career in such an environment
Post Views:
2,512 -
Health-Tech Connections
Challenges in health care delivery have compounded, with clinical staff being exposed to the Omicron COVID variant. Reduced staffing has brought on its challenges to most already-strained state health care systems and the people working in them.
However, over the past 2 years of the pandemic, technology has played an increasing role on the front end for patients and consumers at home and clinicians in the medical setting. Much more is planned in technology that will deliver efficiency, reduce risk and make available new models of care. This has the potential to touch the working lives of all stakeholders and
recipients of care. -
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.